1. Home
  2. GNPX vs PMAX Comparison

GNPX vs PMAX Comparison

Compare GNPX & PMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • PMAX
  • Stock Information
  • Founded
  • GNPX 2009
  • PMAX 2019
  • Country
  • GNPX United States
  • PMAX Hong Kong
  • Employees
  • GNPX N/A
  • PMAX N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • PMAX
  • Sector
  • GNPX Health Care
  • PMAX
  • Exchange
  • GNPX Nasdaq
  • PMAX Nasdaq
  • Market Cap
  • GNPX 6.2M
  • PMAX 6.6M
  • IPO Year
  • GNPX 2018
  • PMAX 2024
  • Fundamental
  • Price
  • GNPX $0.27
  • PMAX $0.38
  • Analyst Decision
  • GNPX Strong Buy
  • PMAX
  • Analyst Count
  • GNPX 1
  • PMAX 0
  • Target Price
  • GNPX $10.00
  • PMAX N/A
  • AVG Volume (30 Days)
  • GNPX 7.3M
  • PMAX 3.3M
  • Earning Date
  • GNPX 05-13-2025
  • PMAX 05-06-2025
  • Dividend Yield
  • GNPX N/A
  • PMAX N/A
  • EPS Growth
  • GNPX N/A
  • PMAX N/A
  • EPS
  • GNPX N/A
  • PMAX 0.04
  • Revenue
  • GNPX N/A
  • PMAX $5,970,263.00
  • Revenue This Year
  • GNPX N/A
  • PMAX N/A
  • Revenue Next Year
  • GNPX N/A
  • PMAX N/A
  • P/E Ratio
  • GNPX N/A
  • PMAX $7.84
  • Revenue Growth
  • GNPX N/A
  • PMAX 30.05
  • 52 Week Low
  • GNPX $0.22
  • PMAX $0.28
  • 52 Week High
  • GNPX $4.09
  • PMAX $4.70
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 44.92
  • PMAX N/A
  • Support Level
  • GNPX $0.23
  • PMAX N/A
  • Resistance Level
  • GNPX $0.44
  • PMAX N/A
  • Average True Range (ATR)
  • GNPX 0.04
  • PMAX 0.00
  • MACD
  • GNPX 0.00
  • PMAX 0.00
  • Stochastic Oscillator
  • GNPX 26.65
  • PMAX 0.00

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About PMAX Powell Max Limited Class A Ordinary Shares

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. Key revenue is derived from Hong Kong.

Share on Social Networks: